(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Revolution Medicines's earnings in 2026 is -$1,371,701,000.On average, 23 Wall Street analysts forecast RVMD's earnings for 2026 to be -$1,701,281,928, with the lowest RVMD earnings forecast at -$1,835,515,334, and the highest RVMD earnings forecast at -$1,594,069,532. On average, 22 Wall Street analysts forecast RVMD's earnings for 2027 to be -$1,265,501,700, with the lowest RVMD earnings forecast at -$2,237,620,282, and the highest RVMD earnings forecast at $214,297,234.
In 2028, RVMD is forecast to generate -$600,733,823 in earnings, with the lowest earnings forecast at -$1,485,496,519 and the highest earnings forecast at $1,151,847,631.